Nuclear IKKa regulates gene transcription by phosphorylating specific substrates and has been linked to cancer progression and metastasis. However, the mechanistic connection between tumorigenesis and IKKa activity remains poorly understood. We have now analyzed 288 human colorectal cancer samples and found a significant association between the presence of nuclear IKK and malignancy. Importantly, the nucleus of tumor cells contains an active IKKa isoform with a predicted molecular weight of 45 kDa (p45-IKKa) that includes the kinase domain but lacks several regulatory regions. Active nuclear p45-IKKa forms a complex with nonactive IKKa and NEMO that mediates phosphorylation of SMRT and histone H3. Proteolytic cleavage of FL-IKKa into p45-IKKa is required for preventing the apoptosis of CRC cells in vitro and sustaining tumor growth in vivo. Our findings identify a potentially druggable target for treating patients with advance refractory CRC.
INTRODUCTION
NF-kB is a transcription factor that regulates innate and acquired immune responses, inflammation, and cancer (Hayden and Ghosh, 2004; Hayden et al., 2006; Schulze-Luehrmann and Ghosh, 2006) . In the absence of stimulation, NF-kB dimers (such as p65/p50) are primarily cytoplasmic and bound to the inhibitor of kB (IkB). Induction of canonical NF-kB pathway by specific stimuli, such as tumor necrosis factor (TNF)-a, bacterial and viral products, or DNA damage, leads to the activation of the IKK (IkB kinase) complex that phosphorylates IkB inducing its degradation and nuclear translocation of the NF-kB factor. The IKK complex is composed of two catalytic subunits, IKKa/IKK1 and IKKb/IKK2, and the regulatory IKKg/NEMO (for NF-kB Essential Modifier). Molecular weight of IKKa and IKKb is 85 and 87 kDa, respectively, and they share 50% of amino acid identity and 70% of structural similarity. IKKa and b contain an amino-terminal kinase domain, a leucine zipper (LZ) region involved in protein dimerization and a helix-loop-helix (HLH) (DiDonato et al., 1997; Zandi et al., 1997) . Recently, LZ and HLH regions of IKK have been redefined based on structural data of IKKb (Xu et al., 2011) . It is established that IKKb and NEMO are essential mediators of IkB degradation and canonical NF-kB activation. Conversely, activation of IKKa by LTb, CD40, or BAFF induces processing of p100 into p52. Then, p52/RelB dimers translocate to the nucleus and activate specific gene transcription. This signaling pathway, known as alternative NF-kB, is required for secondary lymphoid organogenesis (Senftleben et al., 2001) .
In addition to its cytoplasmic functions, nuclear roles for IKKa have recently been identified such as binding to the chromatin of specific promoter regions to phosphorylate serine 10 of histone H3, which affects chromatin condensation and facilitates transcriptional activation of NF-kB-dependent and -independent genes (Anest et al., 2003 (Anest et al., , 2004 Park et al., 2005; Yamamoto et al., 2003) . Nuclear IKKa also regulates cell-cycle progression through phosphorylation of the AuroraB kinase (Prajapati et al., 2006) and derepression of 14-3-3s (Zhu et al., 2007b) . In cancer cells, chromatin-bound IKKa activates the metastasis-related gene, maspin, through epigenetic modifications (Luo et al., 2007) and associates with other factors such as Notch to regulate specific transcription (Hao et al., 2010; Song et al., 2008; Vilimas et al., 2007) . Moreover, IKKa activates cIAP2 and IL-8 transcription through phosphorylation of the nuclear corepressor SMRT at serine 2410, which induces its cytoplasmic export and degradation (Hoberg et al., 2004) . We previously demonstrated that colorectal cancer (CRC) cells contain nuclear IKKa, which phosphorylates SMRT and N-CoR leading to the activation of Notch-target genes hes1 and herp2 (Ferná ndez-Majada et al., 2007a . This is important since Notch activity is required for CRC progression (Fre et al., 2005; van Es et al., 2005) . Interestingly, inhibition of IKK activity reverted Notch-target gene expression and reduced tumor xenografts growth in nude mice (Ferná ndez-Majada et al., 2007a . However, IKK activity is essential for multiple physiological functions, including regulation of immune response, differentiation of lymph nodes, mammary gland, and skin, and maintenance of liver and gut homeostasis (Luedde et al., 2007; Nenci et al., 2007; Pasparakis et al., 2002) , and consequently, cannot be inhibited without producing severe undesirable effects (Chen et al., 2003; Greten et al., 2007; Maeda et al., 2005) .
In this work, we study the traits that distinguish CRC-related IKK functions from those associated with physiological NF-kB, which has critical implications for further identification of therapeutic druggable targets. We show that nuclear localization of active IKKa is a common event associated with advanced human CRC, and identify a truncated form of IKKa (referred to as p45-IKKa) that represents the majority of active IKK in this cellular compartment. Truncated IKKa is generated by cathepsin activity, which is increased in CRC. At the biochemical level, active p45-IKKa is in a nuclear complex with NEMO, which specifically phosphorylates SMRT leading to specific gene transcription. Knocking down IKKa prevents growth of CRC cells both in vitro and in vivo, and this effect is rescued by small hairpin RNA (shRNA)-resistant IKKa but not by a cleavagedefective mutant. Together, our results indicate the possibility to target p45-IKKa generation or activation as a strategy for CRC treatment.
RESULTS

CRC Cells Contain a Nuclear Form of IKKa of 45 kDa
Activation of nuclear IKKa has been previously associated with human CRC and prostate metastasis in mouse (Ferná ndez-Majada et al., 2007a; Luo et al., 2007) . We here analyze a total of 288 samples (147 adenomas and 141 carcinomas) and the corresponding paired distal normal mucosa from 98 patients and found that more than 60% of the adenomas and 85% of the carcinomas show high P-IKK staining (considering ++ plus +++ intensities) compared with adjacent normal tissues (19% positive), as detected by immunohistochemistry (IHC) with two antibodies recognizing phosphorylated serines 180/ 181 of IKKa and b, respectively (a-P-IKK, Cell Signaling no. 2681 and Santa Cruz sc-23470) ( Figures 1A and 1B ). Most of the positive samples showed strong punctuate cytoplasmic staining; in addition 30% of adenomas and 40% of carcinomas contain detectable levels of nuclear P-IKK ( Figures 1A, 1C , and 1D). Confocal microscopy confirmed the presence of nuclear P-IKK in 11 out of 12 randomly selected samples identified as nuclear positive in the general screening, and its absence in 12 out of 12 negative samples (96% correspondence). A more detailed analysis revealed that, even in the positive tumors, most of P-IKK was localized in cytoplasmic vesicles, being the nuclear staining restricted to discrete dots ( Figure S1A ; data not shown). To further investigate the nature of tumor-associated nuclear IKK, we performed subcellular fractionation followed by western blot analysis of fresh CRC samples and normal adjacent mucosa (N) from 4 different patients and 2 human carcinomas grown as xenograft in nude mice (CRCX). We found that most of the active P-IKK corresponding to the expected size of 85-87 kDa was localized in the cytoplasm of tumor and normal cells. Unexpectedly, the same antibody recognized a double band of around 45 kDa that was highly enriched in both the cytoplasmic and nuclear fractions of carcinoma cells (from now on p45-IKK) ( Figure 1E ). Active p45-IKK was also detected in human CRC cell lines using two different a-P-IKK antibodies (Cell Signaling no. 2681 and no. 2697) ( Figure 1F ) and from extracts obtained in the presence of specific protease inhibitors (Figure S1B, lanes 2 and 3) or directly boiled in 1% SDS sample buffer and electrophoresed without further manipulation ( Figure S1B, lane 4) . a-IKKa antibody, but not a-IKKb, recognized bands compatible with p45-IKK in all tested CRC cells ( Figure 1F ) and human CRC samples ( Figure 1E ), suggesting that p45-IKK was an isoform of IKKa. Of note, that nonphosphorylated p45-IKK was also detected in the cytoplasm of nontransformed cells ( Figure 1E ). To further demonstrate that p45-IKK was a product of IKKa, we performed knockdown experiments in HCT116 and Ls174T cells, followed by western blot analysis. We found that different shRNA targeting IKKa reduced both the 85 kDa and the 45 kDa bands detected with a-IKKa antibody from total ( Figure 1G ) and nuclear extracts ( Figure S1C ). In contrast, IKKb levels were not affected, demonstrating the specificity of the shRNA, although we observed a reduction of NEMO levels (Figures 1G and S1D) that did not affect canonical NF-kB activity as detected by IkBa phosphorylation after TNF-a treatment ( Figure S1D ). Besides, we detected low levels of p45-IKKa in mouse embryonic fibroblasts (MEFs) that were absent from IKKa knockout (KO) MEFs ( Figure S1E ) supporting the IKKa nature of p45. Importantly, antibodies recognizing phosphorylated IKK failed to detect this band (data not shown), as in normal human samples ( Figure 1D ), suggesting that p45-IKKa is inactive in nontransformed cells. Further demonstrating that p45-IKKa is phosphorylated in CRC, treatment of HCT116 nuclear extracts with calf intestinal alkaline phosphatase (CIAP) abrogated detection of p45-IKK by a-P-IKK ( Figure S1F ). These results indicate the existence of an IKKa species with an apparent size of 45 kDa that represents the majority of active IKK in the nucleus of CRC cells. Conversely, nontransformed cells contain nonphosphorylated p45-IKKa, which is localized in the cytoplasm.
Generation of the Nuclear p45-IKKa Form Present in CRC Cells
We tested the possibility that high levels of p45-IKKa found in CRC cells were due to mutations in the IKKa sequence that translate into a truncated protein. Because of its inferred molecular size, we focused on studying the region involving exons 13-15 of IKKa, which was found to be mutated in squamous cell carcinomas (Liu et al., 2006) . First, we performed singlestrand conformational polymorphism (SSCP) analysis of this region, amplified using intronic primers from genomic DNA corresponding to 161 human CRC samples (5 stage I, 52 stage II, 83 stage III, and 21 stage IV). In this screening, we did not detect any alteration beyond a single nucleotide change in an intronic region of sample 515T ( Figure S2A ; data not shown). By direct sequencing, we confirmed the absence of mutation in this region using genomic DNA from HCT116, HT-29, and SW480 cells, as well as 16 human CRC samples. Interestingly, analysis of the cDNA identified a deletion of exon 14 in one of the samples that led to a frameshift that generates a premature STOP codon at position 520 (data not shown). Together, these data indicate that mutation of the IKKa gene is not the main mechanism contributing to p45-IKKa generation. Next, we investigated whether p45-IKKa was produced by FL-IKKa processing. With this objective, we transduced HEK293T, HCT116, and HT-29 cells with a retroviral vector codifying for FL-IKKa fused to the myc epitope at the N-terminal end (myc-IKKa). Western blot analysis of the lysates demonstrated the presence of the expected 85 kDa IKKa protein, in addition to a 45 kDa that was recognized with the a-myc antibody (Figure 2A ). In HEK293T cells, myc-IKKa generated a pattern of bands that was identical to the endogenous IKKa from CRC cells ( Figure S2B ), although p45 was more prominent in CRC cells. Identity of the 45 kDa band was further established by precipitation of HA-IKKa with the a-HA antibody followed by detection with specific a-IKKa antibody generated against its N-terminal end ( Figure 2B ) and by conventional mass spectrometry analysis of the tryptic peptides (data not shown). Generation of p45-IKKa from HA-IKKa was not modified by mutation of serines 176 and 180 to alanine (S176/180A) or glutamic acid (S176/180E), indicating its activation status was not necessarily linked with cleavage ( Figure S2C ). These results indicate that FL-IKKa generates p45-IKKa, which comprises the N-terminal kinase and the ubiquitin-like domain (ULD) but lacks the regulatory scafold/dimerization domain (SDD) ( Figure 2C ). Since IKK exhibits a conformation that involves the physical interaction of SDD with the ULD and kinase domains (Xu et al., 2011) , we predicted that p45-IKKa might differentially expose the regions close to the cleavage site compared with FL-IKKa. Based on this, and to further study the distribution and prevalence of p45-IKKa in human samples, we generated monoclonal antibodies against peptide amino acids (aa) 241-424 of human IKKa and tested for their capacity to precipitate p45-IKKa from nondenatured CRC cell lysates. Among these antibodies, we obtained the clone 881H3 that preferentially binds p45-IKKa from tumor cell lysates compared with the full-length (FL) nondenatured form ( Figure S2D ) and generated a specific staining pattern in WT MEF that was not detected in IKKa KO cells (Figure S2E) . In CRC cells, staining with the 881H3 antibody was found in the nucleus and cytoplasm and was lost in cells treated with shRNA against IKKa ( Figure S2F ). Thus, we selected 881H3 to study the distribution of p45-IKKa by IHC in human samples. In CRC samples, 881H3 generated a specific staining pattern that resembled active P-IKKa including cytoplasmic vesicles and discrete nuclear dots ( Figures 2D and 2E ). By double IHC and confocal microscopy analysis, we detected a substantial colocalization of p45-IKKa with P-IKK in CRC ( Figure 2F ). As a control, staining with 881H3 in CRC was lost after incubation with the blocking peptide ( Figure S2G ). Positive staining for p45-IKKa was also detected in normal colonic mucosas previously categorized as negative for P-IKK, mainly restricted to the proliferative basal regions ( Figure S2H ). By crossing our data from active IKK (P-IKK) and p45-IKKa expression, we found that detection of p45-IKKa levels was independent of P-IKK status in the normal mucosa but it was associated in the CRC group of samples ( Figures 2D and 2G) . A more detailed study of the correlation between p45-IKKa and P-IKK staining demonstrated that p45-IKKa levels significantly and positively correlated with P-IKK reactivity in CRC samples ( Figure 2H ).
Cathepsin-Mediated Processing Generates p45-IKKa In Vitro
To identify putative proteases that mediate IKKa processing, we created a Python script and queried for candidates using the information in the MEROPS peptidase database (Rawlings et al., 2010) . This search was performed using the region including exons 13-14 as a target sequence (aa 300-450). We identified three putative cleavage sites for caspase 3/6/7, cathepsin B/L and cathepsin K that could account for the generation of p45-IKKa ( Figure 3A) . To test whether these sites were functional, we designed an expression vector containing the myc tag fused to the aa 300-450 IKKa fragment that includes all three sites. We found that this IKKa fragment expressed in HEK293T cells generated a 25 kDa band when incubated at acid pH (optimal for cathepsin activity), which was further increased after incubation with nuclear extracts from Ls174T CRC cells ( Figure 3B ). Treatment with z-FA-FMK, a specific inhibitor of cathepsin B and L (Sillence and Allan, 1997) but not with the caspase inhibitor z-VAD (not shown), significantly reduced IKKa processing in these experiments ( Figure 3C ). Next, we generated point mutants of the FL-IKKa construct to disrupt each of the identified protease recognition sites individually and in combination. As shown in Figure 2A , we found that myc-IKKa expressed in HCT116 cells was efficiently processed into p45-IKKa; however, single mutations in cathepsin or caspase sites, and the triple mutation of all three protease recognition sites (3M) reduced IKKa cleavage (from 45% in the WT to 9%-10%, 12%, and 6% in the mutants, respectively). Similarly, the IKKa-3M mutant failed to be processed in nontransformed cells ( Figure 3D ). These results suggest that all three sites might contribute to some extent to p45-IKKa generation. To further define the cleavage site for p45-IKKa generation, we performed a more detailed analysis of the mass spectrometry data obtained from the precipitated HA-p45-IKKa fragment. In these experiments we failed to detect most of the central region of the IKKa protein (were cleavage is predicted to occur) but we identified a single peak (extracted ion chromatogram) compatible with the expected end-terminal (G) A group of 183 human colon tumors and 55 normal mucosas, previously characterized for P-IKK, were analyzed by IHC for the presence of p45-IKKa. Tables represent the distribution of p45-IKKa staining in samples categorized as negative or positive (+, ++, and +++) for P-IKK. Statistical analysis demonstrated that P-IKK and p45-IKK expression was distributed randomly in the normal mucosa (X-square test, p = 0.07) but strongly associated in the CRC samples (p = 0.0001). (H) Spearman Rho test demonstrated a linear positive correlation between P-IKK and p45-IKK levels, which reached statistical significance (p = 0.01). See also Figure S2 . sequence generated from Cathepsin B/L cleaved IKKa protein after trypsin digestion (peptide TVYEGPFAS). In contrast, we did not detect any tryptic peptide with the characteristics of a Caspase-or Cathepsin K-processed IKKa fragment (not shown). Together, these results indicate that p45-IKKa is generated by specific protease activity, most likely through cathepsins.
p45-IKKa Is Generated by Cathepsin-Dependent Processing In Vivo To investigate the putative involvement of cathepsins in generating p45-IKKa in vivo, we ectopically expressed FL-IKKa alone or together with cathepsin B, L, K or caspase 3 in HEK293T cells. We found that expression of either cathepsin homolog increased generation of p45-IKKa compared with cells transfected with control vector ( Figure 4A ) or caspase 3 ( Figure S3A ). In agreement with the possibility that cathepsins mediate IKKa cleavage in CRC cells, we found increased levels of cathepsin L ( Figure 4B) and B (data not shown) in both nuclear and cytoplasmic lysates, associated with high cathepsin B/L activity ( Figure 4C ) in all tested CRC cell lines compared with nontransformed HS27 cells. However, cathepsin B/L activity does not strictly correlate with levels of active p45-IKKa in each individual cell line, indi-cating that cathepsin-mediated processing is a tightly regulated process. Most important, abrogation of cathepsin B/L activity by the pharmacological inhibitor z-FA-FMK mostly abolished formation of endogenous nuclear p45-IKKa in CRC cells ( Figures  4D and S3B ). By IF followed by confocal microscopy analysis, we detected high levels of cathepsin B and L in human primary CRC tumors that colocalized with P-IKK in specific ring-shaped cytoplasmic vesicles reminiscent of lysosomal or endosomal structures ( Figures 4E and S3C ). In these vesicles, P-IKK appeared restricted to the membrane rings where it costains with the specific a-IKKa antibody ( Figure S3D ), when compared with the more central localization of cathepsins B or L. Different controls for cross-reaction of antibodies or cross-contamination of fluorochromes were performed ( Figure S3E ). Further characterization of these structures demonstrated that they contained RAB5, a small GTPase protein involved in trafficking of early endosomes (Poteryaev et al., 2010) (Figure 4F ), and we found colocalization between P-IKK and some vesicles positive for the late endosomal marker RAB7 ( Figure 4G) . In contrast, P-IKK detection absolutely diverged from staining with the autophagosomal marker LC3 ( Figure S3F ) and the lysosomal marker LAMP1 (Figure S3G) , excluding the possibility that in cancer cells active p45-IKKa is part of a degradation product. Of note, in these samples cathepsin B was only partially distributed in the lysosomal particles ( Figure S3H ). Together, these results indicate that cathepsin activity is mainly responsible for generating p45-IKKa in CRC cells and suggest that the interaction between IKKa and cathepsins takes place in specific endosomal vesicles. Sorting of IKKa into these vesicles might contribute to regulate IKKa processing.
Truncated IKKa Displays Specific Biochemical Properties
To study the biochemical characteristics of p45-IKKa, we performed gel filtration experiments in Superdex S200 columns from HCT116 ( Figure 5A ) and SW480 nuclear extracts (Figure S4A) and determined the distribution of active IKKa in the different fractions. We found that active/phosphorylated p45-IKKa coeluted with the nonactive FL-IKKa and NEMO in the high molecular weight (HMW) fractions (19-25) (larger than 210 kDa), whereas FL-active P-IKKa was recovered in low molecular weight (LMW) fractions 38-45, likely corresponding to monomeric IKKa (Figures 5A and S4A) . Further suggesting that p45-IKKa was in a HMW complex with nonactive FL-IKKa and NEMO, p45-IKKa expressed in IKKa KO MEFs eluted in intermediate molecular weight fractions 26-36 ( Figure 5B , left panels) and partially shifted to HMW fractions 19-24 when FL-IKKa was reintroduced, coeluting with exogenous IKKa and NEMO ( Figure 5B, right panels) . Existence of this complex was confirmed by precipitation of endogenous NEMO from fractionated nuclear HCT116 extracts (fractions 20-25) ( Figure 5C ) and total cell lysates ( Figure S4B ) and detection of both p45 and FL-IKKa in the precipitates. Different amounts of NEMO, FL-IKKa, and p45-IKKa in the precipitates from the fractions suggest the existence of specific complexes with diverse stoichiometries. To study whether IKKb participates in this complex, we precipitated myc-p45-IKKa expressed in HEK293T cells together with HA-IKKa or HA-IKKb. We found that HA-IKKa but not HA-IKKb associated with p45-IKKa in these conditions ( Figure 5D ).
Nuclear IKKa has been shown to be associated with the chromatin through histone H3 (Zhu et al., 2007a) . By pull-down assays, we found that FL-IKKa but not p45-IKKa alone associates with histone H3 ( Figure 5E) ; however, p45-IKKa can bind histone H3 in the presence of FL-IKKa ( Figure 5E ). In agreement with these results, we found that IKKa associates with histone H3 through its C-terminal region ( Figure S4C ). Importantly, ectopically expressed p45-IKKa localized essentially in the cytoplasm (although it retains the NLS sequence, see Figure 2C ) in the absence of endogenous IKKa, and was redistributed into the nuclear and chromatin compartments in the presence of ectopic FL-IKKa, as shown by western blot from IKKa-deficient MEFs ( Figure 5F ). However, treatment of these cells with the nuclear export inhibitor Leptomycin B resulted in the accumulation of both FL-IKKa and p45-IKKa in the nucleus (Figure S4D) , indicating that NLS is functional in p45-IKKa but its chromatin binding and nuclear retention require the participation of FL-IKKa.
p45-IKKa Promotes Phosphorylation of Specific Substrates Both In Vitro and Vivo
We have previously shown that SMRT and N-CoR corepressors are substrates for IKKa kinase in CRC cells (Ferná ndez-Majada et al., 2007a . To identify the nuclear fraction that contains this kinase activity, we performed immunoprecipitations of Superdex S200 fractions 19-25 (HMW) and 38-45 (LMW) from HCT116 nuclear extracts with either a-IKKa or a-P-IKK antibodies and assayed the capacity of the precipitates to phosphorylate glutathione S-transferase (GST)-N-CoR or GST-SMRT fusion proteins. Precipitates obtained from the HMW fractions (19-25) containing active p45-IKKa, but not precipitates from fractions 38-45 (LMW) including active FL-IKKa ( Figure 6A) , phosphorylated both N-CoR ( Figure 6B ) and SMRT ( Figure S5A ) in vitro.
To further test whether p45-IKKa was involved in phosphorylating nuclear substrates in vivo, we transfected HA-FL-IKKa, truncated active MT-p45-IKKa or both constructs in IKKa KO MEFs and measured their effect on different substrates by western blot analysis. In agreement with the in vitro data, active p45-IKKa induced SMRT phosphorylation in serine 2410 and this effect was enhanced by FL-IKKa. In addition, combination of active p45-IKKa and FL-IKKa induced phosphorylation of histone H3 ( Figure 6C) . These results indicate that p45-IKKa is required for specific nuclear IKKa kinase activities, although p45-IKKa by itself was unable to associate ( Figure S5B ) or phosphorylate SMRT or NCoR in vitro (not shown). We also measured the transcriptional effects of reintroducing FL-or p45-IKKa in IKKa KO cells. As shown in Figure 6D , ectopic expression of FL-IKKa induced the activation of several genes known to be repressed by SMRT such as hes1, herp2, and hes5. This effect was potentiated by p45-IKKa coexpression whereas p45-IKKa alone did not have any transcriptional effect.
Next, we investigated whether phosphorylation of nuclear IKKa targets and transcription of SMRT-repressed genes in CRC cells depends on p45-IKKa. To do this, we transduced HCT116 or HT-29 cells with retroviral vectors containing an IRES-GFP and codifying for WT IKKa, the IKKa 3M mutant alone or 3M together with p45-IKKa. Next, we sorted the GFP positive cells and knocked down endogenous IKKa using shRNA that targets its 3 0 untranslated region (UTR) (shRNAno. 4, Figures 1G and S1C) , which does not affect the IKK constructs. Efficiency of endogenous IKKa depletion and expression of the different IKKa constructs was confirmed by western blot of sorted cells ( Figure 6E ). We found that WT IKKa, but not the IKKa-3M mutant, restored or even increased phosphorylation of SMRT and histone H3 in IKKa knocked down CRC cells. Similar effects were observed when p45-IKKa was coexpressed with noncleavable IKKa (Figure 6E) . In contrast, IKKa-3M efficiently binds to IKKb (Figure S5C ), induces IkBa phosphorylation ( Figure 6F) and was activated by the IKK kinase TAK1 ( Figure 6G ). Most importantly, changes in SMRT phosphorylation induced by IKKa reconstitution correlated with changes in the transcriptional activity of specific SMRT targets, including the antiapoptotic gene cIAP2 ( Figure 6H ).
Truncated P-IKKa Is Required for Preventing Apoptosis and Supporting the Growth of CRC Cells Finally, we measured the contribution of IKKa and p45-IKKa activities to CRC. Indicative of their functional relevance, knocking down IKKa significantly inhibits the growing capacity of all tested CRC cell lines ( Figure 7A ). Using the same strategy as before (transducing WT IKKa or the 3M mutant or the IKKa mutant plus p45-IKKa, followed by endogenous IKKa knockdown), we tested whether p45-IKKa was required to revert IKKa depletion in CRC cells. We found that the effects of IKKa knockdown in CRC cell growth were specifically rescued by WT IKKa or by the IKKa 3M mutant plus p45-IKKa but not by IKKa 3M alone ( Figure 7B ). Flow cytometry analysis demonstrated that only IKKa or 3M plus p45-IKKa protected CRC cells from apoptosis, as measured by annexin V binding ( Figure 7C ) and induced a slight, but significant, increase in cell proliferation ( Figure 7D ). Prosurvival effects of p45-IKKa can be explained, at least in part, by regulation of CIAP2 (Deveraux et al., 1998) . We next determined the capacity of HCT116 and HT-29 cells depleted from endogenous IKKa and reconstituted with WT or the noncleavable IKKa mutant to grow as tumor xenografts in nude mice. CRC cells expressing WT IKKa generated significantly larger tumors than cells expressing the IKKa mutant ( Figures 7E-7G and S6 ), indicating the pathological relevance of p45-IKKa.
In summary, we have identified a cathepsin-dependent mechanism that generates truncated IKKa, which is found in the nucleus of tumor cells in its active form, where it is responsible for specific kinase activities that directly impinge on cancer cell growth both in vitro and in vivo.
DISCUSSION
Our results indicate that human CRC tumors display constitutive nuclear IKKa phosphorylation, associated with increased tumor grade. In tumor cells, we found that IKKa is proteolytically processed into a 45 kDa fragment, in a cathepsin-dependent manner. Moreover, p45-IKKa and P-IKK levels showed a significant correlation in CRC samples. At the functional level, we found that nuclear active p45-IKKa coelutes and interacts with nonphosphorylated FL-IKKa and NEMO and is capable of phosphorylating SMRT and N-CoR corepressors and histone H3. Cleavage of IKKa into p45-IKKa is required for tumor growth in vitro and in vivo, although we detected some p45-IKKa and P-IKK staining in few normal samples mainly restricted to the proliferative compartment. The physiological significance of p45-IKKa and the mechanisms regulating its generation, activation, and nuclear translocation are currently being investigated.
Although IKKa is mostly found in the cytoplasm associated with IKKb and NEMO, we here demonstrate that truncated p45-IKKa translocates to the nuclear compartment in CRC cells where it interacts with FL-IKKa and NEMO. Which are the mechanisms regulating formation of this IKK complex remain unknown, but they might include availability of IKK components (i.e., low amounts of nuclear IKKb compared with nuclear IKKa and intermediate levels of NEMO), posttranslational modifications of specific elements and the participation of adaptor proteins.
On the other hand, it is known that IKKa phosphorylates specific nuclear targets such as histone H3 and nuclear corepressors (Anest et al., 2003; Hoberg et al., 2004; Yamamoto et al., 2003) . Here, we show that p45-IKKa is required for SMRT and histone H3 phosphorylation. By analysis of the elution fractions from Superdex S200 columns, we detected that all the FL-P-IKKa eluted in a LMW fraction compatible with monomeric IKK, which is unable to phosphorylate SMRT. Which are the substrates of nuclear FL-P-IKK kinase remains to be elucidated. On the other hand, FL-IKKa is required for chromatin binding of p45-IKKa association with SMRT and phosphorylation of SMRT and histone H3 by p45-IKKa, although it retains the kinase domain and NLS sequences. In this sense, it has been recently demonstrated the importance of the SDD domain of IKKb (that is conserved in IKKa) not only for substrate recognition but also for kinase activation (Xu et al., 2011) . We propose that p45-IKKa uses the SDD and NBD domains from FL-IKKa to achieve their functions.
Mechanisms that lead to the formation of p45-IKKa may not be unique and are likely context dependent. Examples include frameshift mutations generating premature STOP codons that are present in squamous cell carcinoma (Liu et al., 2006) and splicing variants that codify for proteins lacking the SDD as it was found in T-lymphocytes and in the brain (McKenzie et al., 2000) . However, we did not find such mutations in around 200 samples analyzed, and identified alternative splicing of exon 14 (leading to truncated IKKa) in only one CRC sample. Thus, we propose that the main source of p45-IKKa in CRC cells is proteolytic processing of IKKa by cathepsins. This is consistent with increased cathepsin activity found in CRC that can be associated with the enhanced aerobic glycolysis, previously described by Warburg (Swietach et al., 2007) , but also with other cancerrelated pathways such as erbB2-K-RAS (Fehrenbacher et al., 2008; Kim et al., 1998) , JAK-STAT (Kreuzaler et al., 2011 ), or vitamin D-cystatin (Alvarez-Díaz et al., 2009 ). In addition, we found that mutations in a caspase consensus site of IKKa also reduced p45-IKKa generation, which might suggest that the presence of adjacent protease binding sites might facilitate cathepsin recognition or that the caspase site is functional under specific conditions. Whether cathepsin-mediated processing is differentially required to generate cytoplasmic or nuclear p45-IKKa is somewhat puzzling and requires further investigation. Most important, in CRC cells cathepsin B and L colocalized with P-IKK in cytoplasmic ring-shape structures, corresponding to endosomal vesicles that express RAB5, suggesting that IKKa processing and activation occurs previous to its nuclear translo-cation. Similar mechanisms of endosomal-mediated processing have been shown to regulate ligand-independent activation of Notch ( through TLR4 (Kagan et al., 2008; Tseng et al., 2010) , death signaling induced by the TNF-a receptor (Schneider-Brachert et al., 2004) , and dorsoventral specification in Drosophila (Lund et al., 2010) . Interestingly, our results indicate that p45-IKKa is not restricted to CRC since nonphosphorylated forms are consistently found in the cytoplasm of nontransformed MEF and human colonic mucosa. However, homozygous mutations of human IKKa leading to a premature STOP codon at position 422 results in a lethal syndrome due to severe fetal malformation defects (Lahtela et al., 2010) , indicating the functional requirement of one FL allele. Further work, including generation of new animal models should decipher the physiological and pathological contribution of p45-IKKa. However, we found that cancer cells lacking IKKa cannot form tumors in vivo when reconstituted with a noncleavable IKKa mutant.
The relevance of this work resides in the characterization of p45-IKKa, which function is not directly related with NF-kB but holds important tumorigenic potential. This finding opens the possibility of designing new anticancer treatments targeting IKKa cleavage that should restrict the negative effects of inhibiting general IKK activity and thus NF-kB. In addition, we have generated an antibody that specifically recognizes p45-IKKa by IHC, IF, and IP of CRC samples, which in the near future will be applicable, likely in combination with P-IKK detection, for analysis of human tumors, stratification of CRC patients, and other clinical-related applications.
EXPERIMENTAL PROCEDURES
Human Colorectal Samples
Samples from patients were obtained from the archives of the Tumor Bank of Hospital del Mar. All patients gave written consent to donate the tumor specimen. The ethics committee of our institution approved the study.
Production of Monoclonal Antibodies against p45-IKKa These antibodies were generated by Abyntek (Spain) using the peptide aa 241-424 of human IKKa as immunogen.
Gel Filtration Assay on Superdex200 Column HCT116 nuclear extracts (100 ml) were lysed in PBS containing 0.5% Triton X-100, 1 mM EDTA, 100 mM Na-orthovanadate, 0.25 mM phenylmethanesulfonylfluoride (PMSF), and complete protease inhibitor cocktail (Roche, Basel, Switzerland), centrifuged, and loaded on Superdex200 gel filtration column (GE Healthcare). One drop (40 ml) per fraction was collected and analyzed by western blot.
Protein Kinase Assays
Nuclear fractions 19-27 and 36-45 from Superdex200 column were precleared and incubated with a-IKKa or a-P-IKKa/b overnight at 4 C. Precipitates were captured with Protein A-Sepharose, washed and assayed for their kinase activity on GST fusion proteins. Kinase reaction was performed at 30 C in 20 mM Tris (pH 7.5), 5 mM MgCl 2 , and 1 mM DTT.
Statistical Methods
Categorical data were compared by use of Fisher's exact test. A nonparametric analysis of variance was used for the analysis of the ordinal expression of P-IKK data by applying a rank transformation on the dependent variable. Analysis was performed using SAS version 9.1.3 software (SAS Institute Inc., Cary, NC), and level of significance was established at 0.05 (two-sided).
Tumor Xenografts HCT116 and HT-29 cells were transduced with different IKKa-retroviral vectors and sorted based on YFP expression. Then, cells were transduced with shRNA vectors, selected for 3 days with puromycin, and tested for the expression of the target proteins. Cells (2 3 10 4 ) were suspended in matrigel and injected subcutaneously in nude mice, and, after 3 weeks, visible tumors were measured and photographed. Animals were kept under pathogen-free conditions and all procedures approved by the Animal Care Committee.
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